Patient Selection and Switching Patients to Subcutaneous Infliximab
Jean-Frederic Colombel, MD, examines considerations for transitioning patients from intravenous to subcutaneous infliximab and evaluates the role of subcutaneous infliximab within the evolving landscape of inflammatory bowel disease treatments.
- For patients currently receiving IV infliximab (originator or biosimilar), are there any considerations for switching them to subcutaneous infliximab?
- How will subcutaneous infliximab fit in with the growing IBD treatment landscape?
Recent Videos
Related Content
